Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.14 HKD | +0.88% | -5.79% | -21.92% |
Apr. 03 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
Apr. 03 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
Business Summary
Number of employees: 219
Sales per Business
HKD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Products
100.0
%
| 63 | 100.0 % | 63 | 100.0 % | -0.57% |
Sales per region
HKD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
China
100.0
%
| 63 | 100.0 % | 63 | 100.0 % | -0.53% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jinzi Wu
CEO | Chief Executive Officer | 61 | - |
Yan Yuemei
CTO | Chief Tech/Sci/R&D Officer | - | - |
Handan He
CTO | Chief Tech/Sci/R&D Officer | - | 19-10-06 |
Zhengqing Li
CTO | Chief Tech/Sci/R&D Officer | - | 19-02-27 |
Chief Operating Officer | 50 | 19-03-12 | |
Joshua Zhongbao
PRN | Corporate Officer/Principal | - | 18-08-29 |
Ming Fai Chung
SEC | Corporate Secretary | 45 | 22-08-21 |
John Gargiulo
PRN | Corporate Officer/Principal | - | 22-06-11 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jinzi Wu
CEO | Chief Executive Officer | 61 | - |
Jiong Gu
BRD | Director/Board Member | 51 | 18-03-31 |
Chief Operating Officer | 50 | 19-03-12 | |
Yizhen Wei
BRD | Director/Board Member | 49 | 18-04-26 |
Lin Hua
BRD | Director/Board Member | 50 | 18-04-26 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 1,042,776,000 | 286,381,323 ( 27.46 %) | 30,018,000 ( 2.879 %) | 27.46 % |
Company contact information
Ascletis Pharma, Inc.
HIPARK, 198 Qidi Road Xiaoshan District
311200, Hangzhou
+86 571 8538 9730
http://www.ascletis.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.92% | 147M | |
+0.82% | 93.19B | |
0.00% | 39.62B | |
-10.35% | 33.78B | |
+65.21% | 26.82B | |
-16.15% | 15.35B | |
-6.98% | 13.13B | |
-11.77% | 11.6B | |
-49.19% | 10.26B | |
+2.92% | 9.43B |
- Stock Market
- Equities
- 1672 Stock
- Company Ascletis Pharma Inc.